Beam Therapeutics BEAM Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $294.94M+4.6% | $281.97M-35.3% | $435.9M+87.3% | $232.77M-58.4% | ||
| $950.27M+67.1% | $568.77M-24.6% | $753.98M-10.8% | $845.37M— | ||
| $6.68M-18.0% | $8.14M-6.6% | $8.72M-31.6% | $12.75M+0.1% | ||
| $99.84M+4.4% | $95.62M+5.5% | $90.6M+51.6% | $59.78M+52.5% | ||
| $1.27B+44.5% | $878.15M-27.5% | $1.21B+10.8% | $1.09B-14.1% | ||
| $104.5M-6.2% | $111.41M-10.8% | $124.96M+8.1% | $115.62M+37.2% | ||
| $100.68M-4.0% | $104.87M-7.1% | $112.85M-4.8% | $118.51M+15.4% | ||
| $634K-49.4% | $1.25M-41.6% | $2.15M+11.1% | $1.93M+12.0% | ||
| $1.48B+34.2% | $1.1B-24.4% | $1.46B+8.8% | $1.34B-9.0% | ||
| $38.03M+155% | $14.9M-42.1% | $25.74M-12.5% | $29.41M-4.4% | ||
| $55.27M+16.4% | $47.47M-57.5% | $111.66M+132% | $48.06M— | ||
| $6.66M-93.9% | $108.86M+58.4% | $68.71M-49.5% | $135.97M+57.6% | ||
| $14.36M+6.6% | $13.47M+5.4% | $12.78M+23.1% | $10.38M+37.7% | ||
| $96.94M-46.8% | $182.07M-11.4% | $205.57M-8.1% | $223.6M+4.8% | ||
| —— | —— | —— | —— | ||
| $139.76M-5.5% | $147.96M-7.5% | $159.91M-5.2% | $168.63M+25.1% | ||
| —— | —— | —— | $1.15M-61.6% | ||
| $173K-65.7% | $504K+69.1% | $298K-78.4% | $1.38M-50.7% | ||
| $242.82M-34.4% | $370.28M-22.6% | $478.39M-21.3% | $608.24M-6.1% | ||
| $1.02M+21.7% | $836K+2.5% | $816K+14.6% | $712K+4.1% | ||
| $2.88B+25.2% | $2.3B+5.9% | $2.17B+21.0% | $1.79B+12.4% | ||
| -$1.64B-4.8% | -$1.57B-31.7% | -$1.19B-12.5% | -$1.06B-37.6% | ||
| $1.11M+63.6% | $679K+12.4% | $604K+125% | -$2.43M-4,760% | ||
| $1.24B+68.8% | $733.55M-25.2% | $981.33M+33.8% | $733.47M-11.3% | ||
| $1.48B+34.2% | $1.1B-24.4% | $1.46B+8.8% | $1.34B-9.0% | ||
| $950.27M+67.1% | $568.77M-24.6% | $753.98M-10.8% | $845.37M— | ||
| $634K-49.4% | $1.25M-41.6% | $2.15M+11.1% | $1.93M+12.0% | ||
| $100.68M-4.0% | $104.87M-7.1% | $112.85M-4.8% | $118.51M+15.4% | ||
| $100.68M-4.0% | $104.87M-7.1% | $112.85M-4.8% | $118.51M+15.4% | ||
| $634K-49.4% | $1.25M-41.6% | $2.15M+11.1% | $1.93M+12.0% | ||
| $100.68M-4.0% | $104.87M-7.1% | $112.85M-4.8% | $118.51M+15.4% | ||
| $634K-49.4% | $1.25M-41.6% | $2.15M+11.1% | $1.93M+12.0% | ||
| $7.7M-8.3% | $8.4M-22.2% | $10.8M-41.0% | $18.3M-56.6% | ||
| $7.7M-8.3% | $8.4M-22.2% | $10.8M-41.0% | $18.3M-56.6% | ||
| $5.95M+426% | $1.13M-58.5% | $2.72M-78.2% | $12.46M-60.3% | ||
| $55.27M+16.4% | $47.47M-57.5% | $111.66M+132% | $48.06M— | ||
| $154.12M-4.5% | $161.43M-6.5% | $172.69M-6.1% | $183.87M+24.5% | ||
| $1.02M+21.7% | $836K+2.5% | $816K+14.6% | $712K+4.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Beam Therapeutics cover its short-term obligations?
- Its current ratio is 16.99 — current assets exceed current liabilities.
- Where does Beam Therapeutics's balance sheet data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.